Sanofi Sees Emerging Market Led By China The Second Largest Insulin Opportunity After U.S.
This article was originally published in PharmAsia News
Executive Summary
Although oral anti-diabetic drugs are widely prescribed and used in developing countries, due to their cost and long history, insulin use has huge growth potential. In China alone, patients on insulin treatment could more than double, says Sanofi SVP for diabetes.